Patents Examined by Claire M. Kaufman
  • Patent number: 6380160
    Abstract: A novel splice-variant of gp130 is disclosed, together with the DNA sequence coding for it, pharmaceutical compositions comprising it and its use in ensuring the correct development of pre-implantation embryos.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: April 30, 2002
    Assignee: Applied Research Systems ARS Holding NV.
    Inventors: Andrew Sharkey, Stephen Kevin Smith, Kimberley Anne Dellow
  • Patent number: 6372491
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: April 16, 2002
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney
  • Patent number: 6372488
    Abstract: Described herein are isolated polynucleotides which code for an AMPA-type human CNS receptor, designated the human GluR4B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing the receptor is disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 16, 2002
    Assignee: NPS Allelix Corp.
    Inventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
  • Patent number: 6368853
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: April 9, 2002
    Assignee: Genentech, Inc.
    Inventors: Paul J. Godowski, Austin L. Gurney
  • Patent number: 6359115
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Xianzhi Mao, Kenneth A. Thomas, Andrew Tebben
  • Patent number: 6358693
    Abstract: Described herein are isolated polynucleotides which code for an AMPA-type human CNS receptor, designated the human GluR4B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing the receptor is disclosed.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: March 19, 2002
    Assignee: NPS Allelix Corp.
    Inventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
  • Patent number: 6355476
    Abstract: Full length cDNAs, L2G25B and 4-1BB, were isolated and sequenced. The cDNA L2G25B encodes for the lymphokine, macrophage inflammatory protein-1&agr; or MIP-1&agr;. The studies disclosed herein suggest that MIP-1&agr; and MIP-&bgr; can, through rapid action, modulate early myeloid progenitor cell proliferation. Recombinant proteins have been produced for the cytokine, L2G25BP (Macrophage Inflammatory Protein-1&agr;, MIP-1&agr;). By employing the recombinant protein (rMIP-1&agr;), receptors for MIP-1&agr; were identified on Con A-stimulated and unstimulated CTLL-R8, a T-cell line, and LPS-stimulated RAW 264.7, a macrophage-cell line. Purified recombinant murine macrophage inflammatory protein-1 alpha (rmuMIP-&agr;), was assessed for effects on proliferation of granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells. The results suggest that rmuMIP-1&agr; has myelosuppressive activity in vivo.
    Type: Grant
    Filed: July 30, 1992
    Date of Patent: March 12, 2002
    Assignee: Advanced Research and TechnologyInc
    Inventors: Byoung Se Kwon, Hal E. Broxmeyer
  • Patent number: 6350450
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: February 26, 2002
    Assignee: Genentech, Inc.
    Inventors: Paul J. Godowski, Austin L. Gurney, Audrey Goddard, Kenneth Hillan
  • Patent number: 6348351
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligand homologues NL2, NL3 and NL6 (FLS139), the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: February 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Sherman Fong, Napoleone Ferrara, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Kenneth Hillan, P. Mickey Williams
  • Patent number: 6348333
    Abstract: A novel polypeptide is provided, which can be utilized to treat diseases accompanying neovascularization, such as solid tumors, and is useful as a low molecular weight VEGF inhibitor. The polypeptide contains immunoglobulin-like domain 1 and immunoglobulin-like domain 2 of the extracellular domain of the VEGF receptor KDR. Since it has smaller molecular weight than the conventional polypeptides with retaining VEGF inhibitory activity, it is expected that it can be readily expressed using recombinant DNA techniques and infiltrates into diseased sites more quickly.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: February 19, 2002
    Assignee: Toa Gosei Co., Ltd.
    Inventors: Mikio Niwa, Masaji Okamoto, Tomoe Matsumoto, Toshiaki Segawa
  • Patent number: 6348350
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: February 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney
  • Patent number: 6346411
    Abstract: An isolated and purified DNA molecule encoding Candida albicans protein with integrin-like motifs, the protein itself, antibodies thereto, and methods of use, are provided.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: February 12, 2002
    Assignee: Regents of the University of Minnesota
    Inventors: Margaret K. Hostetter, Cheryl A. Gale, Catherine M. Bendel, Nian-jun Tao
  • Patent number: 6342363
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.
    Type: Grant
    Filed: January 27, 1998
    Date of Patent: January 29, 2002
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
  • Patent number: 6333311
    Abstract: The invention provides compositions containing human lactoferrin, or lactoferrin variants deleted for one or more arginine residues in the amino-terminal region of the protein (i.e., in the first basic cluster), and methods of using the compositions. The human lactoferrin, or lactoferrin variants are useful for treatment of human diseases and conditions, including inflamation.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: December 25, 2001
    Assignee: Pharming
    Inventors: Jan Nuijens, Patrick van Berkel
  • Patent number: 6271363
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: August 7, 2001
    Assignees: President & Fellows of Harvard College, Imperial Cancer Research Technology, Ltd.
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin
  • Patent number: 6268170
    Abstract: The present invention provides an isolated and purified &agr;-tocopherol transport protein polypeptide. Human recombinant &agr;-tocopherol transport protein, polynucleotides encoding human &agr;-tocopherol transport protein and methods of using &agr;-tocopherol transport protein polypeptides and polynucleotides are also provided.
    Type: Grant
    Filed: November 14, 1995
    Date of Patent: July 31, 2001
    Assignee: Northwestern University
    Inventors: Teepu Siddique, Afif Hentati, Han-Xiang Deng
  • Patent number: 6262026
    Abstract: Chimeric proteins which comprise a ligand-binding domain of a first receptor and a carrier domain which tends a cell surface receptor other than the first receptor, useful in transporting a selected substance present in extracellular fluids, such as blood or lymph, into cells; quantitative assays for the selected substance using chimeric proteins; DNA encoding the chimeric proteins; plasmids which contain DNA encoding the chimeric proteins; mammalian cells, modified to contain DNA encoding the chimeric proteins, which express and, optionally, secrete the chimeric proteins; a method of producing the chimeric proteins; a method of isolating the chimeric proteins; a method of using the chimeric proteins to assay the selected substance; and a method of reducing extracellular levels of the selected substance through administration of the chimeric protein, which results in transport of the selected substance into cells.
    Type: Grant
    Filed: April 2, 1999
    Date of Patent: July 17, 2001
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Michael W. Heartlein, Jeffrey F. Lemontt, Michael F. Concino
  • Patent number: 6261786
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: July 2, 1996
    Date of Patent: July 17, 2001
    Assignees: Imperial Cancer Res. Technology, President & Fellows of Harvard College
    Inventors: Valeria Marigo, Clifford J. Tabin, Philip W. Ingham, Andrew P. McMahon
  • Patent number: 6255059
    Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a yeast expression library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: July 3, 2001
    Assignee: Cadus Pharmaceutical Corporation
    Inventors: Christine A. Klein, Andrew J. M. Murphy, Dana M. Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
  • Patent number: 6242199
    Abstract: An assay for the detection of growth hormone secretagogue receptors and growth hormone secretagogue related receptors is described. As these receptors are a member of the G protein coupled receptors, a subunit of the G protein must be present in order for expression to be detected. A similar assay is described where the presence of growth hormone secretagogues are detected.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: June 5, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Lee-Yuh Pai, Scott D. Feighner, Andrew D. Howard, Sheng-Shung Pong, Leonardus H. T. Van Der Ploeg